The genetic architecture of human infectious diseases and pathogen-induced cellular phenotypes

Authors: Andrew T. Hale[1,2], Dan Zhou[2], Rebecca L. Sale[2], Lisa Bastarache[3], Liuyang Wang[4,5], Sandra S. Zinkel[6], Steven J. Schiff[7], Dennis C. Ko[4], and Eric R. Gamazon[2,8,9,10*]

[1]Vanderbilt University School of Medicine, Medical Scientist Training Program, Nashville, TN.

[2]Vanderbilt Genetics Institute & Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN.

[3]Department of Bioinformatics, Vanderbilt University School of Medicine, Nashville, TN.

[4]Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC.

[5]Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, NC.

[6]Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN.

[7]Centers for Neural Engineering and Infectious Disease Dynamics, Departments of Neurosurgery, Engineering Science and Mechanics, and Physics, Penn State University. University Park, PA.

[8]Clare Hall, University of Cambridge, Cambridge, UK.

[9]MRC Epidemiology Unit, University of Cambridge, Cambridge, UK

[10]Lead Contact.

* Correspondence and requests for materials should be addressed to E.R.G.
(eric.gamazon@vanderbilt.edu)

Abstract

Here, we develop a genetics-anchored framework to decipher mechanisms of infectious disease

(ID) risk and infer causal effect on potential complications. We perform transcriptome-wide

association studies (TWAS) of 35 ID traits in 27,615 individuals in a broad collection of human

tissues, identifying 70 gene-level associations with 26 ID traits, with replication in two large-

scale biobanks. A phenome-scale scan and Mendelian Randomization of the 70 gene-level

associations across 197 traits proposes a molecular basis for known complications of the ID

traits. This rich resource of host genetic associations with pathogen cultures and 16S-rRNA-

based microbiome variation provides a platform to investigate host-pathogen interactions. To

identify relevant cellular processes, we develop a TWAS repository of 79 pathogen-exposure

induced cellular phenotypes. Our study will facilitate mechanistic insights into the role of host

genetic variation on ID risk and pathophysiology, with important implications for our molecular

understanding of severe phenotypic outcomes.

Keywords: PrediXcan; Human Genetics; Infectious Disease; Transcriptomics; TWAS; GWAS;

Electronic Health Records; Hi-HOST; BioVU; UK Biobank; FinnGen; Functional Genomics;

GTEx; PheWAS; Mendelian Randomization; Clinical Microbiology; 16S rRNA; Microbiome

45
46

INTRODUCTION

Genome-wide association studies (GWAS) and large-scale DNA biobanks with phenome-scale information are making it possible to identify the genetic basis of a wide range of complex traits in humans[1,2]. A parallel development is the increasing availability of GWAS summary statistics, facilitating genetic analyses of entire disease classes and promising considerably improved resolution of genetic effects on human disease[3,4]. Recent analysis involving 558 well-powered GWAS results found that trait-associated loci cover ~50% of the genome, enriched in both coding and regulatory regions, and of these, ~90% are implicated in multiple traits[5]. However, the breadth of clinical and biological information in these datasets will require new methodologies and additional high-dimensional data to advance our understanding of the genetic architecture of complex traits and relevant molecular mechanisms[6-8]. Approaches to understanding the functional consequences of implicated loci and genes are needed to determine causal pathways and potential mechanisms for pharmacological intervention.

The genetic basis of infectious disease (ID) risk and severity has been relatively understudied using GWAS methodologies. ID risk and pathogenesis is likely to be multifactorial, resulting from a complex interplay of host genetic variation, environmental exposure, and pathogen-specific molecular mechanisms. Although monogenic mechanisms of ID risk have been demonstrated, characterizing the genetic architecture of ID risk remains challenging[9-13]. Phenome-scale information increasingly available in large-scale DNA biobanks offers opportunities to fill gaps in our understanding of the causal effect of ID risk on other traits, including adverse outcomes.

Here we conduct genome-wide association studies (GWAS) and transcriptome-wide association studies (TWAS) of 35 ID traits. To implement the latter, we apply PrediXcan[7,14], which exploits the genetic component of gene expression to probe the molecular basis of disease risk. We combine information across a broad collection of tissues to determine gene-level associations using a multi-tissue approach, which displays improved statistical power over

a single-tissue approach[7,14,15]. Notably, we identify 70 gene-level associations for 26 of 35 ID

traits, i.e., heretofore referred to as ID-associated genes, and conduct replication using the

corresponding traits in the UK Biobank and FinnGen consortia data[1,16]. The rich resource of

genetic information linked to clinical microbiology information (serology and culture data) across

bacterial, fungal, and viral genera that we leverage provides a platform to interrogate the genetic

basis of compartment-specific infection and colonization. Linking high-resolution taxonomic

classification from 16S ribosomal RNA (rRNA) sequencing to host GWAS information has been

used to investigate the contribution of host genetic variation to microbiome composition[17]. We

exploit host GWAS for 155 pathogens in the microbiome[17] to gain further insights into identified

genetic risk factors for an ID trait. To determine the phenotypic consequences of ID-associated

genes, including adverse outcomes and complications, we perform a phenome-scale scan

across hematologic, respiratory, cardiovascular, and neurologic traits. We use a Mendelian

Randomization framework[18] to conduct causal inference on the effect of a clinical ID trait on an

adverse clinical outcome. To elucidate the cellular mechanisms through which host genetic

variation influences disease risk, we generate an atlas of gene-level associations with 79

pathogen-induced cellular phenotypes determined by High-throughput Human *in vitrO*

Susceptibility Testing (Hi-HOST)[19] as a discovery and replication platform. The rich genomic

resource we generate and the integrative methodology we develop promise to yield discoveries

on the molecular mechanisms of infection, improve our understanding of adverse outcomes and

complications, and enable prioritization of new therapeutic targets.

RESULTS

A schematic diagram illustrating our study design and the reference resource we provide

can be found in Figure 1. Here we analyzed 35 clinical ID traits, 79 pathogen-exposure-induced

cellular traits, and 197 (cardiovascular, hematologic, neurologic, and respiratory) traits. We

performed GWAS and TWAS[14,20] to investigate the genetic basis of the ID traits and their

potential adverse outcomes and complications. We exploited serology and culture data linked to

genetic information and genome-wide associations with microbiome traits to investigate

compartment-specific patterns of infection. We conducted causal inference within a Mendelian

Randomization framework[21], exploiting genetic instruments for naturally "randomized controlled

trials" to evaluate the causal effect of a modifiable exposure or risk factor on a clinical

phenotype. We generate a rich resource for understanding the genetic and molecular basis of

infection and potential adverse effects and complications.

GWAS and TWAS of 35 infectious disease clinical phenotypes implicate broad range of

molecular mechanisms

109   We sought to characterize the genetic determinants of 35 ID traits, including many which

have never been investigated using a genome-wide approach. First, we performed GWAS of

each of these phenotypes using a cohort of 23,294 and 4,321 BioVU individuals of European

and African ancestry, respectively, with extensive EHR information from BioVU[2]. We identified

genome-wide significant associations ($p < 5 \times 10^{-8}$) for 13 ID traits (Figure 2A and Supplementary

Table 1). The SNP rs17139584 on chromosome 7 was our most significant association ($p =$

1.21×10^{-36}) across all traits, with bacterial pneumonia. A LocusZoom plot shows several

additional genome-wide significant variants in the locus (Figure 2B), in low linkage

disequilibrium ($r^2 < 0.20$) with the sentinel variant rs17139584, including variants in the *MET*

gene and in *CFTR*. The *MET* gene acts as a receptor to *Listeria monocytogenes* internalin InlB,

mediating entry into host cells; interestingly, listeriosis, a bacterial infection caused by this

pathogen, can lead to pneumonia[22]. Given the observed associations in the cystic fibrosis gene

CFTR (~650 Kb downstream of *MET*), we also asked whether the rs17139584 association was

driven by cystic fibrosis. Notably, the SNP remained nominally significant, though its

significance was substantially reduced, after adjusting for cystic fibrosis status ($p = 0.007$; see

Methods) or excluding the cystic fibrosis cases ($p = 0.02$). The LD profile of the genome-wide

significant results in this locus (Figure 2B) is consistent with the involvement of multiple

independent loci (e.g., *MET* and *CFTR*) underlying bacterial pneumonia risk. The rs17139584

association replicated (p = 5.3×10^{-3}) in the UK Biobank[1]. Eighty percent to ninety percent of

patients with cystic fibrosis suffer from respiratory failure due to chronic bacterial infection (with

Pseudomonas aeruginosa)[23]. Thus, future studies on the role of this locus in lung infection

associated with cystic fibrosis may provide germline predictors of this complication; alternatively,

the locus may confer susceptibility to lung inflammation, regardless of cystic fibrosis status.

Collectively, our analysis shows strong support for allelic heterogeneity, with likely multiple

independent variants in the locus contributing to interindividual variability in bacterial pneumonia

susceptibility.

Additional examples of genome-wide significant associations with other ID traits were

identified. For example, rs192146294 on chromosome 1 was significantly associated (p =

1.23×10^{-9}) with *Staphylococcus* infection. In addition, 10 variants on chromosome 8 were

significantly associated (p < 1.17×10^{-8}) with Mycoses infection.

Next, to improve statistical power, we performed multi-tissue PrediXcan[7,14,15]. We

constructed an atlas of TWAS associations with these ID traits in separate European and

African American ancestry cohorts (Supplementary Data File 1). Notably, 70 genes reached

experiment-wide or individual ID-trait significance for 26 of the 35 clinical ID traits (Figure 3A

and Table 1). Sepsis, the clinical ID trait with the largest sample size in our data (Figure 3B;

Phecode 994; number of cases 2,921; number of controls 22,874), was significantly associated

(p = 8.16×10^{-7}) with *IKZF5* after Bonferroni correction for the number of genes tested (adjusted p

< 0.05). The significant genes (Table 1) were independent of the sentinel variants from the

GWAS (Supplementary Table 1), indicating that the gene-based test was identifying additional

signals.

Our analysis identified previously implicated genes for the specific ID traits but also

proposes novel genes and mechanisms. ID-associated genes include *NDUFA4* for intestinal

infection, a component of the cytochrome oxidase and regulator of the electron transport chain[24];

AKIRIN2 for candidiasis, an evolutionarily conserved regulator of inflammatory genes in

mammalian innate immune cells[25,26]; *ZNF577* for viral hepatitis C, a gene previously shown to

be significantly hypermethylated in hepatitis C related hepatocellular carcinoma[27]; and epithelial

cell adhesion molecule (*EPCAM*) for tuberculosis, a known marker for differentiating malignant

tuberculous pleurisy[28], among many others. These examples of ID-associated genes highlight

the enormous range of molecular mechanisms that may contribute to susceptibility and

complication phenotypes.

Replication of gene-level associations with infectious diseases in the UK Biobank and FinnGen

To bolster our genetic findings and show that our results were not driven by biobank-

specific confounding, we performed extensive replication, using the biobank with the largest

sample size (for a given trait) as the discovery dataset (see Methods). Here, replication is

defined by concordant direction of effect and statistical significance after Bonferroni adjustment

(adjusted $p < 0.05$) in the test dataset. Replicated genes include *FAM166A* (discovery p =

2.85×10^{-11}, replication p = 2.56×10^{-5}) and *GPATCH11* (discovery p = 2.22×10^{-11}, replication p =

4.39×10^{-3}) for bacterial pneumonia in lung tissue. The complete list of replicated genes by trait

and tissue can be found in Supplemental Data File 2.

We investigated the concordance of results across the datasets. For example, we found

that the genes associated with intestinal infection ($p < 0.05$) in BioVU (discovery dataset) – the

ID trait with the largest sample size in BioVU and with a matching dataset in the independent

FinnGen biobank – showed a significantly greater level of enrichment for gene-level

associations with the same trait in FinnGen (test dataset) compared to the remaining set of

genes (Figure 3C). In particular, higher significance (i.e., lower p-value) was observed in

FinnGen for the intestinal infection associated genes identified in BioVU, which included the top

association *NDUFA4* (BioVU p = 1.83×10^{-9}, FinnGen p = 0.044). These results suggest there

are likely to be additional causal genes among the top associations, which will be identified and

replicated when adequate sample sizes for the biobanks are achieved[12,29].

We identified tissue-level replications for the following ID traits: bacterial pneumonia

(lung, Phecode 480.1), influenza (lung, Phecode 481), meningitis (10 brain regions, Phecode

320), and encephalitis (10 brain regions, Phecode 323) (Supplementary Data Files 2-3). As

before, to improve statistical power to discover tissue-level associations, we used BioVU as the

discovery platform and the UK Biobank as the replication dataset (adjusted p < 0.05, see

Methods) (Figure S1A-G and Supplementary Data File 2). This replication analysis identified

robust gene-level associations with influenza (Figure 3D, Supplementary Data Files 2-3) and

bacterial pneumonia (Figure S1A, Supplementary Data Files 2-3). We provide a longer list of the

top genes (p < 0.05 in BioVU) with nominal associations with influenza (Supplementary Data

Files 2-3) and viral pneumonia (Supplementary Data File 3) in FinnGen (p < 0.05) as a resource

to the community.

We found substantial enrichment for genes with high significance (low p-values) in the

respective brain tissues in the UK Biobank (test dataset) for top gene associations with

meningitis (p < 0.05) in BioVU (discovery dataset) in hippocampus, cerebellar hemisphere, and

hypothalamus (Figure S1B-D, Supplementary Data Files 2-3). Similar enrichment patterns were

observed for the remaining brain tissues (Supplementary Data Files 2-3). Likewise, significant

enrichment results (Figure S1E-G, Supplementary Data Files 2-3) in brain tissues (with BioVU

as discovery dataset and UK Biobank as test dataset) were observed for encephalitis. Using

FinnGen (test dataset), we continued to observe enrichment (though not as pronounced) for

genes with high significance for some ID traits. For example, the top cerebellar gene

associations with meningitis (p < 0.05) in BioVU improved the signal-to-noise ratio for the

cerebellar associations in FinnGen (Figure 3E).

Tissue expression profile of infectious disease associated genes suggests tissue-dependent

mechanisms

The ID-associated genes tend to be less tissue-specific (i.e., more ubiquitously

expressed) than the remaining genes (Figure S2A, Mann Whitney U test on the τ statistic, p =

7.5×10^{-4}), possibly reflecting the multi-tissue PrediXcan approach we implemented, which

prioritizes genes with multi-tissue support to improve statistical power. We hypothesized that

tissue expression profiling of ID-associated genes can provide additional insights into disease

etiologies and mechanisms. For example, the intestinal infection associated gene *NDUFA4* is

expressed in a broad set of tissues, including the alimentary canal, but displays relatively low

expression in whole blood (Figure S2B). In addition, *TOR4A,* the most significant association

with bacterial pneumonia (Table 1), is most abundantly expressed in lung, consistent with the

tissue of pathology, but also in spleen (Figure S2C), whose rupture is a lethal complication of

the disease[30,31]. These examples illustrate the diversity of tissue-dependent mechanisms that

may contribute in complex and dynamic ways to interindividual variability in ID susceptibility and

progression. We therefore provide a resource of gene-level associations with the ID traits in a

broad collection of tissues to facilitate molecular or clinical follow-up studies.

Genetic overlap reveals host gene expression programs and common pathways as targets for

pathogenicity

We hypothesized that ID-associated genes converge on shared functions and pathways,

which may reflect common targeted host transcriptional programs. Among the 70 gene-level

associations with the 35 clinical ID traits, 40 proteins are post-translationally modified by

phosphorylation (Supplementary Table 2), a significant enrichment (Benjamini-Hochberg

adjusted p < 0.10 on DAVID annotations[32]) relative to the rest of the genome, indicating that

phosphoproteomic profiling can shed substantial light on activated host factors and perturbed

signal transduction pathways during infection[33,34]. In addition, 16 proteins are acetylated,

consistent with emerging evidence supporting this mechanism in the host antiviral response[35]

(Supplementary Table 3). These data highlight specific molecular mechanisms across ID traits

with critical regulatory roles (e.g., protein modifications) in host response among the ID-

associated genes.

We tested the hypothesis that distinct infectious agents exploit common pathways to find

a compatible intracellular niche in the host, potentially implicating shared genetic risk factors.

Notably, 64 of the 70 ID-associated genes (Table 1) were nominally associated ($p < 0.05$) with

multiple ID traits (Supplementary Table 4). These genes warrant further functional study as

broadly exploited mechanisms targeted by pathogens or as broadly critical to pathogen-elicited

immune response. Gene Set Enrichment Analysis (GSEA) of these genes implicated a number

of significant (FDR < 0.05) gene sets (Figure 4A), including those involved in actin-based

processes and cytoskeletal protein binding, processes previously demonstrated to mediate host

response to pathogen infection[36]. Since diverse bacterial and viral pathogens target host

regulators that control the cytoskeleton (which plays a key role in the biology of infection) or

modify actin in order to increase virulence, intracellular motility, or intercellular spread[37-39], these

results reassuringly lend support to the involvement of the genes in infectious pathogenesis.

Notably, we identified an enrichment (FDR = 9.68×10^{-3}) for a highly conserved motif

("TCCCRNNRTGC"), within 4 kb of transcription start site (TSS) of multi-ID associated genes

(Figure 4A-B), that does not match any known transcription factor binding site[40] and may be

pivotal for host-pathogen interaction for the diversity of infectious agents included in our study.

In addition, we found that several of the multi-ID associated genes (with the sequence motif

near the TSS) have been observed in host-pathogen protein complexes (by both

coimmunoprecipitation and affinity chromatography approaches) for the specific pathogens

responsible for the ID traits[41]. See Supplementary Data File 4 for complete list of host-pathogen

interactions for these genes/proteins. One example is *CDK5*, a gene significantly associated

with Gram-positive septicemia (Table 1) and nominally associated with multiple ID traits,

including herpes simplex. CDK5 is activated by p35, whose cleaved form p25 results in

subcellular relocalization of CDK5. The CDK5-p25 complex regulates inflammation[42] (whose

large-scale disruption is characteristic of septicemia) and induces cytoskeletal disruption in

neurons[43] (where the herpes virus is responsible for lifelong latent infection). The A and B

chains of the CDK5-p25 complex (Figure 4C for structure diagram[44]) are required for

cytoskeletal protein binding (CDK5), whereas the D and E chains (p25) are involved in actin

regulation and kinase function, all molecular processes implicated in our pathway analysis.

Intriguingly, blocking CDK5 can have a substantial impact on the outcome of inflammatory

diseases including sepsis[45], enhancing the anti-inflammatory potential of immunosuppressive

treatments, and has been shown to attenuate herpes virus replication[46], suggesting that

modulation of this complex is important for viral pathogenesis.

CDK5 is also altered by several other viruses, identified using unbiased mass

spectrometry analysis[47] (Figure 4D), indicating a broadly exploited mechanism (across

pathogens) that is consistent with the gene's multi-ID genetic associations in our TWAS data

(Figure 4D). The CDK5-interaction proteins include: 1) M2_134A1 (matrix protein 2, influenza A

virus), a component of the proton-selective ion channel required for viral genome release during

cellular entry and is targeted by the anti-viral drug amantadine[48]; 2) VE7_HPV16, a component

of human papillomavirus (HPV) required for cellular transformation and trans-activation through

disassembly of E2F1 transcription factor from RB1 leading to impaired production of type I

interferons[49-51]; 3) VE7_HPV31, which has been shown to engage histone deacetylases 1 and 2

to promote HPV31 genome maintenance[52]; 4) VCYCL_HHV8P (cyclin homolog within the

human herpesvirus 8 genome), which has been shown to control cell cycle through CDK6 and

induce apoptosis through Bcl2[53-55]; and 5) F5HC81_HHV8, predicted to act as a viral cyclin

homolog. Overall, these data underscore the evolutionary strategies that pathogens have

evolved to promote infection, including the hijacking of the host transcriptional machinery and

the biochemical alterations of the host proteome.

Serology and culture data reveal insights into clinical infection and pathogen colonization

We exploited extensive clinical microbiological laboratory analysis of blood (Figure 5A), bronchoalveolar lavage, sputum, sinus/nasopharyngeal, and tracheal cultures for bacterial and fungal pathogen genus identification (Figure S3A-D), as well as respiratory viral genus identification (Figure S3E) (see Methods) to evaluate phenotype resolution and algorithm. For example, we found that *Staphylococcus* infection (Phecode = 041.1) performed well in classifying *Staphylococcus aureus* infection based on blood culture data. The area under the Receiver Operating Characteristic (ROC) curve was 0.938 (Figure 5B) with standard error of 0.008 generated from bootstrapping (see Methods). The area under the curve (AUC) quantifies the probability that the Phecode classifier ranks a randomly chosen positive instance of *Staphylococcus aureus* infection in blood higher than a randomly chosen negative one. In comparison, the first principal component (PC) in our European ancestry samples showed AUC of 0.514 (Figure 5B) while sex and age performed even more poorly (AUC $\approx$ 0.50). We then tested a logistic model with the Phecode classifier, age, sex, and the first 5 PCs in the model. The Phecode classifier was significantly associated ($p < 2.2 \times 10^{-16}$) after conditioning on the remaining covariates. The fitted value from the joint model consisting of the remaining covariates showed AUC of 0.568 (Figure 5B). Collectively, culture data for improved resolution of clinical infection and pathogen colonization provide validation of our approach.

To expand these findings and further dissect the complex pathogen-colonization patterns in humans, we utilized host genome-wide associations with human gut microbiome variation for 155 pathogens[17] identified through 16S rRNA sequencing. For example, among the top SNP associations with *Desulfovibrionaceae* (p<0.0001), a sulfate-reduced bacterium associated with intraabdominal infections and inflammatory bowel disease[56,57], we observed an enrichment for SNPs associated with intestinal infection in BioVU (Figure 5C). These data

provide a reference resource to explore how genetically-determined microbiome variation

influences ID trait susceptibility.

Phenome scan of clinical ID-associated genes identifies adverse outcomes and complications

Electronic Health Records (EHR) linked to genetic data may reveal insights into

associated clinical sequalae[58-60]. To assess the phenomic impact of ID-associated genes (Table

1), we performed a phenome-scale scan across 197 hematologic, respiratory, cardiovascular,

and neurologic traits available in BioVU (Figure 6A and Supplementary Data File 5). Correcting

for total number of genes and phenotypes tested, we identified four gene-phenotype pairs

reaching experiment-wide significance (adjusted $p < 0.05$): 1) *WFDC12*, our most significant (p

$= 4.23 \times 10^{-6}$) association with meningitis and a known anti-bacterial gene[61], is also associated

with cerebral edema and compression of brain ($p = 1.35 \times 10^{-6}$), a feared clinical complication of

meningitis[62]; 2) *TM7SF3*, the most significant gene with Gram-negative sepsis ($p = 1.37 \times 10^{-6}$), is

also associated with acidosis ($p = 1.95 \times 10^{-6}$), a known metabolic derangement associated with

severe sepsis[63], and a gene known to play a role in cell stress and the unfolded protein

response[64]; 3) *TXLNB*, the most significant gene associated with viral warts and human

papillomavirus infection ($p = 4.35 \times 10^{-6}$), is also associated with abnormal involuntary

movements, $p = 1.39 \times 10^{-6}$; and 4) *RAD18*, the most significant gene associated with

Streptococcus infection ($p = 2.01 \times 10^{-6}$), is also associated with anemia in neoplastic disease (p

$= 3.10 \times 10^{-6}$). Thus, coupling genetic analysis to EHR data with their characteristic breadth of

clinical traits offers the possibility of determining the phenotypic consequences of ID-associated

genes, including known (in the case of *WFDC12* and *TM7SF3*) potentially adverse health

outcomes and complications.

Mendelian Randomization provides causal support for the effect of infectious disease trait on

identified adverse phenotypic outcomes/complications

Since our gene-level associations with clinical ID diagnoses implicated known adverse

complications, we sought to explicitly evaluate the causal relation between the ID traits and the

adverse outcomes/complications. We utilized the Mendelian Randomization paradigm[18] (Figure

6B), which exploits genetic instruments to make causal inferences in observational data, in

effect, performing randomized controlled trials to evaluate the causal effect of "exposure" (i.e.,

ID trait) on "outcome" (e.g., the complication). Specifically, we conducted multiple-instrumental-

variable causal inference using GWAS [21] and PrediXcan summary results. First, we used

independent SNPs ($r^2 = 0.01$) with association $p < 1.0x10^{-5}$ as genetic instruments. To control

for horizontal pleiotropy and account for the presence of invalid genetic instruments, we utilized

MR-Egger regression and weighted-median Mendelian Randomization (see Methods)[65,66].

We found causal support for the effect of 1) Gram-negative sepsis on acidosis (Figure

6C, weighted-median estimator $p = 2.0x10^{-7}$); and 2) meningitis on cerebral edema and

compression of brain (Figure 5C, weighted-median estimator $p = 2.7x10^{-3}$). Our resource

establishes a platform to elucidate the genetic component of an ID trait and its impact on the

human disease phenome, enabling causal inference on the effect of an ID trait on potential

complications.

TWAS of 79 pathogen-exposure induced cellular traits highlights cellular mechanisms and

enables validation of ID gene-level associations

Elucidating how the genes influence infection-related cellular trait variation may provide

a mechanistic link to ID susceptibility. We thus performed TWAS of 79 pathogen-induced

cellular traits – including infectivity and replication, cytokine levels, and host cell death, among

others[19] (Supplementary Data File 6). We identified 38 gene-level associations reaching trait-

level significance ($p < 2.87x10^{-6}$, correcting for number of statistical tests; Figure 7A). In addition,

we replicated SNP associations with the cellular traits using the genetic associations with the ID

traits (Supplementary Data File 7) that map to the specific cellular phenotypes (Supplementary

Data File 8).

Integration of EHR data into Hi-HOST[19] may provide additional functional support for the

gene-level associations with a clinical ID trait. For example, we observed a marked enrichment

for genes associated with direct *Staphylococcus* toxin exposure cellular response in Hi-HOST

among the human Gram-positive septicemia associated genes from BioVU (see Supplementary

Data File 6 for genes with FDR < 0.05) (Figure 7B). In addition, integration of EHR data into Hi-

HOST may improve the signal-to-noise ratio in Hi-HOST TWAS data. Indeed, the top 300 genes

nominally associated with Staphylococcus infection (Phecode 041.1) in BioVU departed from

null expectation for their associations with Staphylococcus toxin exposure in Hi-HOST

compared to the full set of genes, which did not (Figure 7C), as perhaps expected due to the

modest sample size. Collectively, these results demonstrate that integrating the EHR-derived

TWAS results into TWAS of the cellular traits can greatly improve identification of potentially

relevant pathogenic mechanisms.

Phenome scan of TWAS findings from Hi-HOST

To identify potential adverse effects of direct pathogen exposure, we performed a

phenome-scan across the 197 cardiovascular, hematologic, neurologic, and respiratory traits as

described above. Our top gene-phenotype pairs include: 1) *FAM171B*, our most significant

association with interleukin 13 (IL-13) levels is also associated with alveolar and parietoalveolar

pneumonopathy (p = 4.04×10^{-5}), a phenotype known to be modulated by IL-13 dependent

signaling[67]; 2) *OSBPL10*, the most significant gene associated with cell death caused by

Salmonella enterica serovar Typhimurium, is also associated with intracerebral hemorrhage (p =

4.99×10^{-5}), a known complication of *S. Typhimurium* endocarditis[68]. These data highlight the

utility of joint genetic analysis of pathogen-exposure-induced phenotypes and clinical ID traits to

gain insights into the molecular and cellular basis of complications and adverse outcomes.

However, more definitive conclusions will require larger sample sizes and functional studies.

DISCUSSION

ID susceptibility is a complex interplay between host genetic variation and pathogen-

exposure induced mechanisms. While GWAS has begun to identify population-dependent loci

conferring ID risk[69], the underlying function of identified variants, predominantly in non-coding

regulatory regions, remains poorly understood. Molecular characterization of infectious

processes has been, in general, agnostic to the genetic architecture of clinical infection.

Although pathogen exposure is requisite to display clinical ID traits, characterizing the role of

host genetic variation remains challenging.

Our study provides a reference atlas of genetic variants and genetically-determined

expression traits associated with a diverse set of clinical ID traits. We identified 70 gene-level

associations in BioVU, with replication for a subset of ID traits in the UK Biobank and FinnGen.

To provide additional support to our findings, we leveraged a rich resource of genetic

information linked to serologic tests and pathogen cultures from five clinical sample sites and

exploited a large catalog of genome-wide associations of microbiome variation generated from

16S rRNA based taxonomic classification. A phenome scan across 197 hematologic, respiratory,

cardiovascular, and neurologic traits proposes a molecular basis for the link between certain ID

traits and outcomes. Using Mendelian Randomization, we determined the ID traits which, as

exposure, show significant causal effect on outcomes. Finally, we developed a TWAS catalog of

79 pathogen-exposure induced cellular traits (Hi-HOST) in a broad collection of tissues, which

provides a platform to interrogate mediating cellular and molecular mechanisms.

Genetic predisposition to ID onset and progression is likely to be complex[70]. Monogenic

mechanisms conferring ID risk have been proposed, but these mechanisms are unlikely to

explain the broad contribution of host genetic influence on ID risk[71]. Thus, a function-centric

methodology is necessary to disentangle potentially causal pathways. Our approach builds on

PrediXcan, which estimates the genetically-determined component of gene expression[14]. The

genetic component of gene expression can then be tested for association with the trait, enabling

insights into potential pathogenic mechanisms[4] and novel therapeutic strategies[72]. Leveraging

the shared regulatory architecture of gene expression[7] can help prioritize gene mechanisms for

downstream functional studies to provide an avenue to identify causal cell types and genes. Our

results highlight a multi-tissue approach to infer causal genes and pathways relevant to ID

biology.

Our study identified genes with diverse functions, including roles in mitochondrial

bioenergetics[24,73], regulation of cell death[74], and of course links to host immune response[75-84].

These diverse functions may contribute to pleiotropic effects on clinical outcomes and

complications. In addition, we identified genes implicated in Mendelian diseases, for which

susceptibility to infection is a predominant feature, including *WIPF1* (OMIM #614493; recurrent

infections and reduced natural killer cell activity[85]), *IL2RA* (OMIM #606367; recurrent bacterial

infections, recurrent viral infections, and recurrent fungal infections[79]), and *TBK1* (OMIM

#617900; herpes simplex encephalitis (HSE), acute infection, and episodic HSE[86]). These

examples show that the identified genes may also confer predisposition, with near-complete

penetrance, to an infectious disease related trait displaying true Mendelian segregation.

Enrichment analysis of 64 of the 70 ID-associated genes with nominal support for

associations with other clinical ID traits identified modulation of the actin cytoskeleton as a

potential shared mechanism of host susceptibility to infection (Figure 4). While manipulation of

the actin cytoskeleton by pathogens is hardly a new concept, our study identified specific host

genetic variation in actin regulatory genes that is potentially causative of clinical ID

manifestations. In addition to pathogen interaction with the cytoskeletal transport machinery,

efficient exploitation of host gene expression program is crucial for successful invasion and

colonization, and here we mapped several pathogenicity-relevant targets. Notably, we observed

a significant enrichment for a highly conserved sequence motif, within 4 kb of a multi-ID-

associated gene's TSS, that is not a known transcription factor binding site. The motif's

presence near multi-ID associated genes suggests a broad regulatory role in host-pathogen

interaction, involving the diversity of pathogens examined here, towards successful

reprogramming of host gene expression. Furthermore, we identified a significant enrichment for

phosphorylated host proteins, suggesting the value of global phosphoproteomic profiling, which

has recently been used to prioritize pharmacological targets for the novel SARS-CoV-2 virus[87].

These data highlight several potential avenues by which host susceptibility can be breached by

a pathogen's requirement to maintain a niche through manipulation of host cellular machinery.

To obtain additional support for our gene-level associations, we leveraged two genomic

resources with rich phenotypic information (UK Biobank[1] and FinnGen[16]). These data will prove

increasingly useful to characterizing the genetic basis of the ID-associated adverse outcomes

and complications. Despite the caveats for the use of EHR in genetic analyses of ID traits[12,29],

the growing availability of such independent datasets will facilitate identification of robust genetic

associations. Perhaps more importantly, the breadth of clinical phenotypes in these EHR

datasets should enable identification of associated adverse outcomes and complications for the

ID-associated genes.

The primary challenges in conducting GWAS of ID traits include phenotype definition

and case-control misclassification. Obstacles to accurate phenotype definition include the

requirement of specialized laboratory testing to identify specific pathogens and administration of

prophylactic therapeutics complicating identification of potentially causative pathogens.

Seropositivity may result from the complex genetic properties of the pathogen and the particular

mechanisms governing host-pathogen interaction. However, seropositivity may not indicate

clinical manifestations of the disease. On the other hand, seronegativity may imply lack of

exposure to the pathogen, the absence of infection even in the presence of exposure, or host

resistance to infection. Anchoring the analysis to host genetic information (as in our use of

genetically-determined expression) and replication of discovered associations may address

some aspects of this challenge. Here we exploit an extensive resource of culture data (for

identification of pathogens from clinical specimens) linked to whole-genome genetic information

to provide additional support to our gene-level associations. One of the ubiquitous problems in

diagnosis is that culture recovery is often for multiple organisms, or a contaminant not relevant

to the actual pathogen. Similarly, molecular diagnostics of pathogen identification is often a

curation of multiple statistically relevant putative pathogens. The mapping of pathogen genome

identification to transcriptional response (molecular seropositivity) is a valuable validation of a

finding that a given pathogen is associated with a particular infectious syndrome, and our

approach to identification of genetically-determined expression changes may facilitate this

mapping. Future studies may also implement more complex GWAS models, including

incorporating the pathogen genome.

The catalog of TWAS associations with microbiome composition may facilitate insights

into molecular mechanisms of infectious disease risk and complications, inform studies of host-

pathogen interactions, and improve anti-microbial pharmacologic strategies. Improved

characterization of pathogen colonization and taxonomic classification at species and strain

level through 16S rRNA sequencing-based approaches may lead to greater resolution of

causative infectious processes. Disruption of pathogen equilibrium in the microbiome by

environmental or genetic variation may determine susceptibility to human disease[88,89]. However,

critical challenges to understanding the patterns of host colonization include identification of rare

pathogen populations as well as environmental pressures (i.e. medication use, dietary

alterations, etc.) acutely altering the microbiome landscape[90]. Thus, linking microbiome traits to

host genetic variation promises to improve resolution of causative mechanisms for ID traits and

potentially adverse outcomes.

Mendelian Randomization provides a framework to perform causal interference on the

effect of the exposure on the outcome[18,21] using genetic instruments. We leveraged a summary

statistics based approach to test the causal effect of an ID trait on potential adverse outcomes.

Mendelian Randomization requires three assumptions: 1) the genetic instrument is associated

with exposure (i.e., ID trait); 2) the genetic instrument is associated with the outcome (i.e.,

adverse outcome or complication) only through the exposure of interest; and 3) the genetic

instrument is affecting the outcome independent of other factors (i.e., confounders). Violations

of these assumptions can have critical implications for the interpretation of the results. Thus,

several approaches have been developed that are robust to these violations. In the case of ID

traits, a methodology that distinguishes causality from comorbidity is critical. While many

phenotypes are highly comorbid and suspected to have a causal relationship (e.g., smoking and

depression/anxiety), Mendelian Randomization does not necessarily support the causal

hypothesis[91]. Furthermore, since RCTs cannot be ethically conducted for ID traits and adverse

outcomes, the methodology offers an approach for elucidating the role of an infection phenotype

or pathogen exposure in disease causation using an observational study design. Here, we

found strong causal support for the effect of certain clinical ID traits on potential adverse

complications identified through a phenome scan of the ID-associated genes: 1) meningitis -

cerebral edema and compression of brain; and 2) Gram-negative sepsis - acidosis.

To enable investigations into mediating cellular and molecular traits for the ID-associated

genes, we provide a functional genomics resource built on a high-throughput *in vitro* pathogen

infection screen (Hi-HOST)[19]. Integration of EHR data into Hi-HOST facilitates replication of

gene-level associations with clinical ID traits and greatly improves the signal-to-noise ratio. This

discovery and replication platform, encompassing human phenomics and cellular microbiology,

provides a high-throughput approach to linking host cellular processes to clinical ID traits and

adverse outcomes.

Although additional mechanistic studies are warranted, our study provides a foundation

for anchoring targeted molecular studies in human genetic variation. Elucidation of host

mechanisms exploited by pathogens requires multi-disciplinary approaches. Here, we show the

broader role of host genetic variation, implicating diverse disease mechanisms. Our study

generates a rich resource and exploits a genetics-anchored methodology to facilitate

investigations of ID-associated clinical outcomes and complications. Causal inference on the

clinical ID traits and potential complications promises to expand our understanding of the

molecular basis for the link and, crucially, enable prediction and prevention of serious adverse

events.

METHODS

BioVU

BioVU, one of the largest DNA biobanks tied to an EHR database, is a subset of the

synthetic derivative (SD), a deidentified electronic health record, consisting of individuals with

whole-genome genetic information. Detailed information on the construction, utilization, ethics,

and policies of the BioVU resource is described elsewhere[2]. ID traits were defined based on a

hierarchical grouping of International Classification of Diseases, Ninth Revision (ICD-9) codes

into phenotype codes (Phecode) representing clinical traits, as previously described[59,92]. (See

below for a description of pathogen culture and viral test data in the BioVU individuals, including

genera detected from different types of cultures.) We used version 1.2 of the Phecode Map

containing 1,965 Phecodes based on 20,203 ICD-9 codes, which substantially improves signal-

to-noise and more accurately reflects the clinical trait. Phecodes may exclude related

phenotypes (e.g., in the case of Gram negative septicemia (Phecode = 038.1), the range of

Phecodes given by 010-041.99, involving bacterial infection) and, importantly, include the

definition of the appropriate control group[93]. Detailed description of Phecode trait maps can be

found at phewascatalog.org. As an efficient and viable model for human genetics research, the

Phecode system has been used to perform phenome-wide association studies (PheWAS) for

validation of known genetic associations and discovery of new genetic disorders[59,60].

Pathogen culture and virology data linked to whole-genome genetic information

For individuals with whole-genome genetic information, we analyzed pathogen (bacterial,

mycobacterial, and fungal) culture data derived from the following positive cultures for the

indicated clinical samples: 1) blood (n = 7,699), 2) sputum (n = 2,478), 3) sinus/nasopharyngeal

(n = 1,820), 4) bronchial-alveolar lavage (n = 1,265), and 5) tracheal sampling (n = 422).

Furthermore, we analyzed a respiratory panel containing 28 viral strains from 2,890 individuals

with whole-genome genetic information. Viral strains included the following: 1) Adenovirus, 2)

Bocavirus, 3) Bordetella parapertussis, 4) Bordetella pertussis, 5) Chlamydia pneumoniae, 6)

Coronavirus 229E, 7) Coronavirus HKU1, 8) Coronavirus NL63, 9) Coronavirus NOS, 10)

Coronavirus OC43, 11) Enterovirus/Rhinovirus, 12) Human Metapneumovirus, 13) Influenza A,

14) Influenza A, H1, 15) Influenza A, H1N1, 16) Influenza A, H3, 17) Influenza B, 18)

Mycoplasma pneumoniae, 19) Parainfluenza, 20) Parainfluenza 1, 21) Parainfluenza 2, 22)

Parainfluenza 3, 23) Parainfluenza 4, 24) Respiratory syncytial virus (RSV), 25) RSV, A, 26)

RSV, B, and 27) Rhinovirus. The pathogen information for each individual in our study included:

1) Total number of cultures; 2) Number of negative cultures (i.e., no pathogen growth); 3)

Number of ambiguous cultures (i.e., normal upper respiratory bacteria or low level

contamination); 4) Number of positive cultures (i.e., the number of cultures with growth

consistent with clinical infection); 5) Genus or genera isolated (up to 96 unique genera per

sample site), which ranged from zero to 10 per sample.

GWAS of ID traits

GWAS of the ID traits were performed on the 23,294 and 4,321 BioVU individuals of

European and African ancestry, respectively. Quality control pre-processing and SNP-level

imputation were conducted, as previously described[60]. Genomic ancestry was quantified using

principal components analysis of the genotype data[94,95]. GWAS of the ID traits were conducted

in separate European and African genomic ancestry cohorts. Within each genomic ancestry, the

association analysis was performed using age, gender, batch, and the first five principal

components as covariates.

Conditional SNP-level analysis

We performed conditional analysis on the top GWAS association with the ID trait (in this

case, bacterial pneumonia) to determine whether it was driven by a related covariate (in this

case, cystic fibrosis status). We used logistic regression to model the conditional probability of

the infectious disease:

572
$$\ln \frac{P(Y=1\,|\,s)}{1-(P(Y=1\,|\,s))} = \beta_0 + \beta_1 s + \beta_2(CF)$$

where s is the genotype at the sentinel variant, Y is the disease (i.e., bacterial pneumonia)

status, and CF is the covariate of interest (i.e., cystic fibrosis).

Transcriptome-wide association studies (TWAS) using PrediXcan

We performed multi-tissue PrediXcan[7,14,15] in the 23,294 and 4,321 BioVU individuals of

European and African ancestry, respectively. As in the GWAS analyses, these were conducted

in the separate genomic ancestry cohorts. Experiment-wide significance (adjusted $p < 0.05$) was

determined using Bonferroni correction for the total number of genes tested (n = 9,868) across

35 phenotypes (i.e., $p < 1.4 \times 10^{-7}$). Trait-specific significance (adjusted $p < 0.05$) was determined

using Bonferroni correction for the total number of genes tested (n = 9,868, $p < 5.07 \times 10^{-6}$).

Genomic ancestry was quantified using principal components analysis[94,95]. TWAS results were

visualized using PhenoGram[96].

GWAS and TWAS Replication

For each ID trait, replication of GWAS and TWAS was performed using the cohort with

the largest sample size (among BioVU[2], the UK Biobank[1], and FinnGen consortia[16]) as

discovery and the remaining biobank(s) as replication. We used the UK Biobank

(http://www.nealelab.is/uk-biobank) and the FinnGen (https://www.finngen.fi/en/access_results)

summary results to generate the gene-level associations. GTEx v6p models (in 44 tissues) were

used to generate tissue-level results.

Classification of pathogen infection based on serology and culture data using several classifiers

Let X be a classifier (e.g., the Phecode or a logistic regression classifier) of serology and

culture data based infection for a given pathogen, with probability density $\varphi_+(x)$ for positive

instances and probability density $\varphi_-(x)$ for negative instances. The ROC curve plots the

specificity (SP) and sensitivity (SN) at various thresholds:

$$SN(T) = \int_T^{\infty} \varphi_+(x)dx$$

$$SP(T) = 1 - \int_T^{\infty} \varphi_-(x)dx$$

599   The area Ω under the curve (AUC) is given by:

$$\Omega = \int_{-\infty}^{\infty} SN(T)SP'(T)dT = \int_{-\infty}^{\infty}\int_T^{\infty} \varphi_+(x)\,\varphi_-(T)dxdT = \int_{-\infty}^{\infty}\int_{-\infty}^{\infty} I(x > T)\,\varphi_+(x)\varphi_-(T)dxdT$$

600   where $I(A)$ is the indicator function, i.e., equal to one if $(x, T) \in A$ and zero otherwise. The last

601   equals the probability that the classifier X ranks a randomly chosen positive instance (of culture

602   data based infection) higher than a randomly chosen negative instance. We note that the

603   expression for Ω suggests other metrics of interest, for example:

$$\Omega_c = \int_c^1 SN(SP)dSP$$

$$c = \underset{t}{\mathrm{argmin}} \sqrt{(1-t)^2 + (1-SN(t))^2}$$

Here $(c, SN(c))$ is the point on the ROC curve closest to true positive rate of 1 and false positive

rate of 0. We estimated the sampling distribution of Ω (including standard error), using

bootstrapping (n = 100) [97]. We used the pROC package for visualization.

Leveraging GWAS of human microbiome traits to extend GWAS of ID traits

We leveraged genome-wide associations of microbiome traits, involving 155 pathogens

derived from phylogenetic analysis of 16S rRNA gene sequences[17].

Causal inference by Mendelian Randomization

To infer causality between the infectious diseases and potential complications, we

performed Mendelian Randomization (MR[18,21]) in 23,294 individuals of European ancestry in

BioVU. To define instrumental variables (IVs), we clumped the exposure-associated SNPs with

high linkage disequilibrium (LD) using Plink1.9 (p < 1×10^{-5}, r^2 = 0.01). Only biallelic non-

palindromic variants were considered as IVs. Considering the pervasive horizontal pleiotropy in

human genetic variation[98], we applied summary statistics based MR-Egger regression[65]. MR-

Egger regression generalizes the inverse-variance weighted method, where the intercept is

assumed to be zero. We also used the weighted-median estimator[66] to test the causal effect of

the exposure trait on the outcome. We leveraged the R package 'MendelianRandomization'.

High-throughput Human in vitrO Susceptibility Testing (Hi-HOST)

We generated an atlas of TWAS associations with 79 pathogen-induced cellular traits –

including infectivity and replication, cytokine levels, and host cell death[19] using the Hi-HOST

platform[99,100]. A list of populations, pathogens and project description may be found at

http://h2p2.oit.duke.edu/About/, and phenotype definitions and family-based GWAS of the Hi-

HOST Phenome Project were previously described[19]. Briefly, lymphoblastoid cell lines (LCLs)

from the 1000 Genomes Consortium[101] were obtained from the Coriell Institute. The LCLs

represented diverse populations, including ESN (Esan in Nigeria), GWD (Gambians in Western

Divisions in the Gambia), IBS (Iberian Population in Spain), and KHV (Kinh in Ho Chi Minh City,

Vietnam). LCLs were cultured in RPMI 1640 media containing 10% fetal bovine serum, 2 mM

glutamine, 100 U/ml of penicillin-G, and 100 mg/ml streptomycin for 8 days prior to experimental

use, as previously described[19]. *Chlamydia trachomatis* infection of LCLs was performed using *C.*

trachomatis LGV-L2 Rif^R pGFP::SW2[102]. *Salmonella* infection was performed using

pMMB67GFP[103], and sifA deletion was constructed using lambda red and validated using

PCR[100,104]. *Candida albicans* SC5314 infection was performed as previously described[105] and

levels of fibroblast growth factor 2 were measured using enzyme linked immunosorbent assays.

Staphylococcus aureus toxin (alpha-hemolysin) was obtained from Sigma and applied to LCLs

at a concentration of 1 μg/ml for 23 hours. Cell death was measured using 7-AAD staining and

flow cytometry. Additional experimental details can be found at http://h2p2.oit.duke.edu/About/.

We estimated the gene-level effect size on the Hi-HOST phenotypes, using GWAS

summary statistics[106] in each of the 44 GTEx tissues (version 6p)[107]. The gene expression

prediction model was trained using GTEx as the reference dataset

(https://zenodo.org/record/3572842/files/GTEx-V6p-HapMap-2016-09-08.tar.gz). The gene-level

effect size was estimated using S-PrediXcan after allele harmonization[106]. We also applied

MultiXcan to improve the ability to identify potential target genes[15]. In brief, MultiXcan regresses

the cellular trait on the principal components of the predicted expression data across all the

available tissues. For each gene, MultiXcan yields a joint effect estimate across the 44 tissues.

We applied the summary-statistic based version (S-MultiXcan) and followed the guides from the

tool's webpage https://github.com/hakyimlab/MetaXcan.

Data and software availability

All code is available at the project's GitHub page:

https://github.com/gamazonlab/infectiousDiseaseResource. Further information and requests

for resources and reagents should be directed to and will be fulfilled by the Corresponding

Author, Eric R. Gamazon (eric.gamazon@vanderbilt.edu).

663   REFERENCES
664
665   1   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
666   *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).

667   2   Roden, D. M. *et al.* Development of a large-scale de-identified DNA biobank to enable
668   personalized medicine. *Clinical pharmacology and therapeutics* **84**, 362-369,
669   doi:10.1038/clpt.2008.89 (2008).

670   3   Cotsapas, C. *et al.* Pervasive sharing of genetic effects in autoimmune disease. *PLoS*
671   *Genet* **7**, e1002254, doi:10.1371/journal.pgen.1002254 (2011).

672   4   Gamazon, E. R., Zwinderman, A. H., Cox, N. J., Denys, D. & Derks, E. M. Multi-tissue
673   transcriptome analyses identify genetic mechanisms underlying neuropsychiatric traits.
674   *Nat Genet* **51**, 933-940, doi:10.1038/s41588-019-0409-8 (2019).

675   5   Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex
676   traits. *Nat Genet*, doi:10.1038/s41588-019-0481-0 (2019).

677   6   Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits.
678   *Nat Genet* **47**, 1236-1241, doi:10.1038/ng.3406 (2015).

679   7   Gamazon, E. R. *et al.* Using an atlas of gene regulation across 44 human tissues to
680   inform complex disease- and trait-associated variation. *Nat Genet* **50**, 956-967,
681   doi:10.1038/s41588-018-0154-4 (2018).

682   8   Shi, H., Kichaev, G. & Pasaniuc, B. Contrasting the Genetic Architecture of 30 Complex
683   Traits from Summary Association Data. *Am J Hum Genet* **99**, 139-153,
684   doi:10.1016/j.ajhg.2016.05.013 (2016).

685   9   Chapman, S. J. & Hill, A. V. Human genetic susceptibility to infectious disease. *Nat Rev*
686   *Genet* **13**, 175-188, doi:10.1038/nrg3114 (2012).

687   10   de Bakker, P. I. & Telenti, A. Infectious diseases not immune to genome-wide
688   association. *Nat Genet* **42**, 731-732, doi:10.1038/ng0910-731 (2010).

689   11   Hill, A. V. The genomics and genetics of human infectious disease susceptibility. *Annu*
690   *Rev Genomics Hum Genet* **2**, 373-400, doi:10.1146/annurev.genom.2.1.373 (2001).

691   12   Ko, D. C. & Urban, T. J. Understanding human variation in infectious disease
692   susceptibility through clinical and cellular GWAS. *PLoS Pathog* **9**, e1003424,
693   doi:10.1371/journal.ppat.1003424 (2013).

694   13   van de Vosse, E., van Dissel, J. T. & Ottenhoff, T. H. Genetic deficiencies of innate
695   immune signalling in human infectious disease. *Lancet Infect Dis* **9**, 688-698,
696   doi:10.1016/s1473-3099(09)70255-5 (2009).

697   14   Gamazon, E. R. *et al.* A gene-based association method for mapping traits using
698   reference transcriptome data. *Nat Genet* **47**, 1091-1098, doi:10.1038/ng.3367 (2015).

15   Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues improves
association detection. *PLoS Genet* **15**, e1007889, doi:10.1371/journal.pgen.1007889
(2019).

16   Locke, A. E. *et al.* Exome sequencing of Finnish isolates enhances rare-variant
association power. *Nature* **572**, 323-328, doi:10.1038/s41586-019-1457-z (2019).

17   Hughes, D. A. *et al.* Genome-wide associations of human gut microbiome variation and
implications for causal inference analyses. *Nature microbiology* **5**, 1079-1087,
doi:10.1038/s41564-020-0743-8 (2020).

18   Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian
randomization: using genes as instruments for making causal inferences in epidemiology.
Stat Med **27**, 1133-1163, doi:10.1002/sim.3034 (2008).

19   Wang, L. *et al.* An Atlas of Genetic Variation Linking Pathogen-Induced Cellular Traits to
Human Disease. *Cell Host Microbe* **24**, 308-323.e306, doi:10.1016/j.chom.2018.07.007
(2018).

20   Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association
studies. *Nature genetics* **48**, 245-252, doi:10.1038/ng.3506 (2016).

21   Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal
inference in epidemiological studies. *Human molecular genetics* **23**, R89-98,
doi:10.1093/hmg/ddu328 (2014).

22   García-Montero, M. *et al.* Pneumonia caused by Listeria monocytogenes. *Respiration* **62**,
107-109, doi:10.1159/000196402 (1995).

23   Lyczak, J. B., Cannon, C. L. & Pier, G. B. Lung infections associated with cystic fibrosis.
Clin Microbiol Rev **15**, 194-222, doi:10.1128/cmr.15.2.194-222.2002 (2002).

24   Balsa, E. *et al.* NDUFA4 is a subunit of complex IV of the mammalian electron transport
chain. *Cell Metab* **16**, 378-386, doi:10.1016/j.cmet.2012.07.015 (2012).

25   Tartey, S. *et al.* Essential Function for the Nuclear Protein Akirin2 in B Cell Activation
and Humoral Immune Responses. *J Immunol* **195**, 519-527,
doi:10.4049/jimmunol.1500373 (2015).

26   Tartey, S. *et al.* Akirin2 is critical for inducing inflammatory genes by bridging IkappaB-
zeta and the SWI/SNF complex. *Embo j* **33**, 2332-2348, doi:10.15252/embj.201488447
(2014).

27   Revill, K. *et al.* Genome-wide methylation analysis and epigenetic unmasking identify
tumor suppressor genes in hepatocellular carcinoma. *Gastroenterology* **145**, 1424-
1435.e1421-1425, doi:10.1053/j.gastro.2013.08.055 (2013).

28   Sun, W., Li, J., Jiang, H. G., Ge, L. P. & Wang, Y. Diagnostic value of MUC1 and
EpCAM mRNA as tumor markers in differentiating benign from malignant pleural
effusion. *QJM : monthly journal of the Association of Physicians* **107**, 1001-1007,
doi:10.1093/qjmed/hcu130 (2014).

29   Power, R. A., Parkhill, J. & de Oliveira, T. Microbial genome-wide association studies:
lessons from human GWAS. *Nature Reviews Genetics* **18**, 41-50,
doi:10.1038/nrg.2016.132 (2017).

30   Domingo, P. *et al.* Spontaneous rupture of the spleen associated with pneumonia.
European journal of clinical microbiology & infectious diseases : official publication of the
European Society of Clinical Microbiology **15**, 733-736, doi:10.1007/bf01691960 (1996).

31   Gerstein, A. R., Riegel, N. & Dennis, M. Ruptured Spleen Simulating Pneumonia. *JAMA*
199, 589-589, doi:10.1001/jama.1967.03120080123033 (1967).

32   Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of
large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**, 44-57,
doi:10.1038/nprot.2008.211 (2009).

33   Soderholm, S. *et al.* Phosphoproteomics to Characterize Host Response During
Influenza A Virus Infection of Human Macrophages. *Molecular & cellular proteomics :*
MCP **15**, 3203-3219, doi:10.1074/mcp.M116.057984 (2016).

34   Stahl, J. A. *et al.* Phosphoproteomic analyses reveal signaling pathways that facilitate
lytic gammaherpesvirus replication. *PLoS Pathog* **9**, e1003583,
doi:10.1371/journal.ppat.1003583 (2013).

35   Murray, L. A., Sheng, X. & Cristea, I. M. Orchestration of protein acetylation as a toggle
for cellular defense and virus replication. *Nat Commun* **9**, 4967, doi:10.1038/s41467-
018-07179-w (2018).

36   Taylor, M. P., Koyuncu, O. O. & Enquist, L. W. Subversion of the actin cytoskeleton
during viral infection. *Nat Rev Microbiol* **9**, 427-439, doi:10.1038/nrmicro2574 (2011).

37   Aktories, K. & Barbieri, J. T. Bacterial cytotoxins: targeting eukaryotic switches. *Nat Rev*
Microbiol **3**, 397-410, doi:10.1038/nrmicro1150 (2005).

38   Yu, B., Cheng, H. C., Brautigam, C. A., Tomchick, D. R. & Rosen, M. K. Mechanism of
actin filament nucleation by the bacterial effector VopL. *Nat Struct Mol Biol* **18**, 1068-
1074, doi:10.1038/nsmb.2110 (2011).

39   Zahm, J. A. *et al.* The bacterial effector VopL organizes actin into filament-like structures.
Cell **155**, 423-434, doi:10.1016/j.cell.2013.09.019 (2013).

40   Xie, X. *et al.* Systematic discovery of regulatory motifs in human promoters and 3' UTRs
by comparison of several mammals. *Nature* **434**, 338-345, doi:10.1038/nature03441
(2005).

41   Ammari, M. G., Gresham, C. R., McCarthy, F. M. & Nanduri, B. HPIDB 2.0: a curated
database for host-pathogen interactions. *Database : the journal of biological databases*
and curation **2016**, doi:10.1093/database/baw103 (2016).

42   Na, Y. R. *et al.* The early synthesis of p35 and activation of CDK5 in LPS-stimulated
macrophages suppresses interleukin-10 production. *Science signaling* **8**, ra121-ra121,
doi:10.1126/scisignal.aab3156 (2015).

43 Patrick, G. N. *et al.* Conversion of p35 to p25 deregulates Cdk5 activity and promotes
neurodegeneration. *Nature* **402**, 615-622, doi:10.1038/45159 (1999).

44 Tarricone, C. *et al.* Structure and regulation of the CDK5-p25(nck5a) complex. *Molecular*
cell **8**, 657-669 (2001).

45 Pfänder, P., Fidan, M., Burret, U., Lipinski, L. & Vettorazzi, S. Cdk5 Deletion Enhances
the Anti-inflammatory Potential of GC-Mediated GR Activation During Inflammation.
Frontiers in Immunology **10**, doi:10.3389/fimmu.2019.01554 (2019).

46 Man, A., Slevin, M., Petcu, E. & Fraefel, C. The Cyclin-Dependent Kinase 5 Inhibitor
Peptide Inhibits Herpes Simplex Virus Type 1 Replication. *Scientific reports* **9**, 1260,
doi:10.1038/s41598-018-37989-3 (2019).

47 Davis, Z. H. *et al.* Global mapping of herpesvirus-host protein complexes reveals a
transcription strategy for late genes. *Molecular cell* **57**, 349-360,
doi:10.1016/j.molcel.2014.11.026 (2015).

48 Hay, A. J., Wolstenholme, A. J., Skehel, J. J. & Smith, M. H. The molecular basis of the
specific anti-influenza action of amantadine. *Embo j* **4**, 3021-3024 (1985).

49 Barnard, P., Payne, E. & McMillan, N. A. The human papillomavirus E7 protein is able to
inhibit the antiviral and anti-growth functions of interferon-alpha. *Virology* **277**, 411-419,
doi:10.1006/viro.2000.0584 (2000).

50 Chellappan, S. *et al.* Adenovirus E1A, simian virus 40 tumor antigen, and human
papillomavirus E7 protein share the capacity to disrupt the interaction between
transcription factor E2F and the retinoblastoma gene product. *Proc Natl Acad Sci U S A*
89, 4549-4553, doi:10.1073/pnas.89.10.4549 (1992).

51 Phelps, W. C., Yee, C. L., Münger, K. & Howley, P. M. The human papillomavirus type
16 E7 gene encodes transactivation and transformation functions similar to those of
adenovirus E1A. *Cell* **53**, 539-547, doi:10.1016/0092-8674(88)90570-3 (1988).

52 Longworth, M. S. & Laimins, L. A. The binding of histone deacetylases and the integrity
of zinc finger-like motifs of the E7 protein are essential for the life cycle of human
papillomavirus type 31. *J Virol* **78**, 3533-3541, doi:10.1128/jvi.78.7.3533-3541.2004
(2004).

53 Duro, D. *et al.* Activation of cyclin A gene expression by the cyclin encoded by human
herpesvirus-8. *J Gen Virol* **80 (Pt 3)**, 549-555, doi:10.1099/0022-1317-80-3-549 (1999).

54 Ojala, P. M. *et al.* Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers
apoptosis in cells with high levels of cyclin-dependent kinase 6. *Cancer Res* **59**, 4984-
4989 (1999).

55 Ojala, P. M. *et al.* The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates
Bcl-2. *Nature cell biology* **2**, 819-825, doi:10.1038/35041064 (2000).

56   Goldstein, E. J., Citron, D. M., Peraino, V. A. & Cross, S. A. Desulfovibrio desulfuricans
bacteremia and review of human Desulfovibrio infections. *Journal of clinical microbiology*
41, 2752-2754, doi:10.1128/jcm.41.6.2752-2754.2003 (2003).

57   Loubinoux, J., Bronowicki, J. P., Pereira, I. A., Mougenel, J. L. & Faou, A. E. Sulfate-
reducing bacteria in human feces and their association with inflammatory bowel
diseases. *FEMS Microbiol Ecol* **40**, 107-112, doi:10.1111/j.1574-6941.2002.tb00942.x
(2002).

58   Bastarache, L. *et al.* Phenotype risk scores identify patients with unrecognized
Mendelian disease patterns. *Science (New York, N.Y.)* **359**, 1233-1239,
doi:10.1126/science.aal4043 (2018).

59   Denny, J. C. *et al.* Systematic comparison of phenome-wide association study of
electronic medical record data and genome-wide association study data. *Nature*
biotechnology **31**, 1102-1110, doi:10.1038/nbt.2749 (2013).

60   Unlu, G. *et al.* Phenome-based approach identifies RIC1-linked Mendelian syndrome
through zebrafish models, biobank associations and clinical studies. *Nat Med* **26**, 98-109,
doi:10.1038/s41591-019-0705-y (2020).

61   Hagiwara, K. *et al.* Mouse SWAM1 and SWAM2 are antibacterial proteins composed of
a single whey acidic protein motif. *J Immunol* **170**, 1973-1979,
doi:10.4049/jimmunol.170.4.1973 (2003).

62   Niemöller, U. M. & Täuber, M. G. Brain edema and increased intracranial pressure in the
pathophysiology of bacterial meningitis. *European journal of clinical microbiology &*
infectious diseases : official publication of the European Society of Clinical Microbiology
8, 109-117, doi:10.1007/bf01963892 (1989).

63   Suetrong, B. & Walley, K. R. Lactic Acidosis in Sepsis: It's Not All Anaerobic:
Implications for Diagnosis and Management. *Chest* **149**, 252-261, doi:10.1378/chest.15-
1703 (2016).

64   Isaac, R. *et al.* TM7SF3, a novel p53-regulated homeostatic factor, attenuates cellular
stress and the subsequent induction of the unfolded protein response. *Cell Death Differ*
24, 132-143, doi:10.1038/cdd.2016.108 (2017).

65   Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
instruments: effect estimation and bias detection through Egger regression. *Int J*
Epidemiol **44**, 512-525, doi:10.1093/ije/dyv080 (2015).

66   Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in
Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
Estimator. *Genetic epidemiology* **40**, 304-314, doi:10.1002/gepi.21965 (2016).

67   Zheng, T. *et al.* IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the
murine lung. *J Immunol* **180**, 522-529, doi:10.4049/jimmunol.180.1.522 (2008).

68   Gómez-Moreno, J., Moar, C., Román, F., Pérez-Maestu, R. & López de Letona, J. M.
849   Salmonella endocarditis presenting as cerebral hemorrhage. *Eur J Intern Med* **11**, 96-97,
850   doi:10.1016/s0953-6205(00)00060-1 (2000).

851   69   Tian, C. *et al.* Genome-wide association and HLA region fine-mapping studies identify
852   susceptibility loci for multiple common infections. *Nat Commun* **8**, 599,
853   doi:10.1038/s41467-017-00257-5 (2017).

854   70   Casanova, J. L. Human genetic basis of interindividual variability in the course of
855   infection. *Proc Natl Acad Sci U S A* **112**, E7118-7127, doi:10.1073/pnas.1521644112
856   (2015).

857   71   Casanova, J. L. Severe infectious diseases of childhood as monogenic inborn errors of
858   immunity. *Proc Natl Acad Sci U S A* **112**, E7128-7137, doi:10.1073/pnas.1521651112
859   (2015).

860   72   So, H. C. *et al.* Analysis of genome-wide association data highlights candidates for drug
861   repositioning in psychiatry. *Nat Neurosci* **20**, 1342-1349, doi:10.1038/nn.4618 (2017).

862   73   El-Bacha, T. & Da Poian, A. T. Virus-induced changes in mitochondrial bioenergetics as
863   potential targets for therapy. *The international journal of biochemistry & cell biology* **45**,
864   41-46, doi:10.1016/j.biocel.2012.09.021 (2013).

865   74   Labbé, K. & Saleh, M. Cell death in the host response to infection. *Cell Death Differ* **15**,
866   1339-1349, doi:10.1038/cdd.2008.91 (2008).

867   75   Brouwer, W. P. *et al.* Genome Wide Association Study Identifies Genetic Variants
868   Associated With Early And Sustained Response To (Peg)Interferon In Chronic Hepatitis
869   B Patients: The GIANT-B Study. *Clinical infectious diseases : an official publication of*
870   *the Infectious Diseases Society of America*, doi:10.1093/cid/ciz084 (2019).

871   76   Liang, X. *et al.* Macrophage FABP4 is required for neutrophil recruitment and bacterial
872   clearance in Pseudomonas aeruginosa pneumonia. *Faseb j* **33**, 3562-3574,
873   doi:10.1096/fj.201802002R (2019).

874   77   Pan, Y. *et al.* Survival of tissue-resident memory T cells requires exogenous lipid uptake
875   and metabolism. *Nature* **543**, 252-256, doi:10.1038/nature21379 (2017).

876   78   Saitoh, T. *et al.* Atg9a controls dsDNA-driven dynamic translocation of STING and the
877   innate immune response. *Proc Natl Acad Sci U S A* **106**, 20842-20846,
878   doi:10.1073/pnas.0911267106 (2009).

879   79   Sharfe, N., Dadi, H. K., Shahar, M. & Roifman, C. M. Human immune disorder arising
880   from mutation of the alpha chain of the interleukin-2 receptor. *Proc Natl Acad Sci U S A*
881   **94**, 3168-3171, doi:10.1073/pnas.94.7.3168 (1997).

882   80   Tsuboi, S. & Meerloo, J. Wiskott-Aldrich syndrome protein is a key regulator of the
883   phagocytic cup formation in macrophages. *The Journal of biological chemistry* **282**,
884   34194-34203, doi:10.1074/jbc.M705999200 (2007).

81 Walenna, N. F. *et al.* Chlamydia pneumoniae exploits adipocyte lipid chaperone FABP4
to facilitate fat mobilization and intracellular growth in murine adipocytes. *Biochem*
Biophys Res Commun **495**, 353-359, doi:10.1016/j.bbrc.2017.11.005 (2018).

82 Willis, K. L., Patel, S., Xiang, Y. & Shisler, J. L. The effect of the vaccinia K1 protein on
the PKR-eIF2alpha pathway in RK13 and HeLa cells. *Virology* **394**, 73-81,
doi:10.1016/j.virol.2009.08.020 (2009).

83 Yu, Z. *et al.* USP1-UAF1 deubiquitinase complex stabilizes TBK1 and enhances antiviral
responses. *The Journal of experimental medicine* **214**, 3553-3563,
doi:10.1084/jem.20170180 (2017).

84 Zhang, X. *et al.* Human intracellular ISG15 prevents interferon-alpha/beta over-
amplification and auto-inflammation. *Nature* **517**, 89-93, doi:10.1038/nature13801 (2015).

85 Lanzi, G. *et al.* A novel primary human immunodeficiency due to deficiency in the
WASP-interacting protein WIP. *The Journal of experimental medicine* **209**, 29-34,
doi:10.1084/jem.20110896 (2012).

86 Herman, M. *et al.* Heterozygous TBK1 mutations impair TLR3 immunity and underlie
herpes simplex encephalitis of childhood. *The Journal of experimental medicine* **209**,
1567-1582, doi:10.1084/jem.20111316 (2012).

87 Bouhaddou, M. *et al.* The Global Phosphorylation Landscape of SARS-CoV-2 Infection.
Cell, doi:https://doi.org/10.1016/j.cell.2020.06.034 (2020).

88 Goodrich, J. K. *et al.* Genetic Determinants of the Gut Microbiome in UK Twins. *Cell*
Host Microbe **19**, 731-743, doi:10.1016/j.chom.2016.04.017 (2016).

89 Hall, A. B., Tolonen, A. C. & Xavier, R. J. Human genetic variation and the gut
microbiome in disease. *Nat Rev Genet* **18**, 690-699, doi:10.1038/nrg.2017.63 (2017).

90 Kurilshikov, A., Wijmenga, C., Fu, J. & Zhernakova, A. Host Genetics and Gut
Microbiome: Challenges and Perspectives. *Trends in immunology* **38**, 633-647,
doi:10.1016/j.it.2017.06.003 (2017).

91 Taylor, A. E. *et al.* Investigating the possible causal association of smoking with
depression and anxiety using Mendelian randomisation meta-analysis: the CARTA
consortium. *BMJ Open* **4**, e006141, doi:10.1136/bmjopen-2014-006141 (2014).

92 Denny, J. C. *et al.* PheWAS: demonstrating the feasibility of a phenome-wide scan to
discover gene-disease associations. *Bioinformatics* **26**, 1205-1210,
doi:10.1093/bioinformatics/btq126 (2010).

93 Wei, W.-Q. *et al.* Evaluating phecodes, clinical classification software, and ICD-9-CM
codes for phenome-wide association studies in the electronic health record. *PloS one* **12**,
e0175508-e0175508, doi:10.1371/journal.pone.0175508 (2017).

94 Derks, E. M., Zwinderman, A. H. & Gamazon, E. R. The Relation Between Inflation in
Type-I and Type-II Error Rate and Population Divergence in Genome-Wide Association

Analysis of Multi-Ethnic Populations. *Behavior genetics* **47**, 360-368,
doi:10.1007/s10519-017-9837-3 (2017).

95   Price, A. L. *et al.* Principal components analysis corrects for stratification in genome-
wide association studies. *Nat Genet* **38**, 904-909, doi:10.1038/ng1847 (2006).

96   Wolfe, D., Dudek, S., Ritchie, M. & Pendergrass, S. Visualizing genomic information
across chromosomes with PhenoGram. *BioData Mining* **6**, 18 - 18 (2013).

97   Efron, B. Bootstrap Methods: Another Look at the Jackknife. *Ann. Statist.* **7**, 1-26,
doi:10.1214/aos/1176344552 (1979).

98   Jordan, D. M., Verbanck, M. & Do, R. HOPS: a quantitative score reveals pervasive
horizontal pleiotropy in human genetic variation is driven by extreme polygenicity of
human traits and diseases. *Genome Biol* **20**, 222, doi:10.1186/s13059-019-1844-7
(2019).

99   Ko, D. C. *et al.* Functional genetic screen of human diversity reveals that a methionine
salvage enzyme regulates inflammatory cell death. *Proc Natl Acad Sci U S A* **109**,
E2343-2352, doi:10.1073/pnas.1206701109 (2012).

100   Ko, D. C. *et al.* A genome-wide in vitro bacterial-infection screen reveals human variation
in the host response associated with inflammatory disease. *Am J Hum Genet* **85**, 214-
227, doi:10.1016/j.ajhg.2009.07.012 (2009).

101   Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74,
doi:10.1038/nature15393 (2015).

102   Saka, H. A. *et al.* Quantitative proteomics reveals metabolic and pathogenic properties
of Chlamydia trachomatis developmental forms. *Molecular microbiology* **82**, 1185-1203,
doi:10.1111/j.1365-2958.2011.07877.x (2011).

103   Pujol, C. & Bliska, J. B. The ability to replicate in macrophages is conserved between
Yersinia pestis and Yersinia pseudotuberculosis. *Infect Immun* **71**, 5892-5899,
doi:10.1128/iai.71.10.5892-5899.2003 (2003).

104   Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in
Escherichia coli K-12 using PCR products. *Proc Natl Acad Sci U S A* **97**, 6640-6645,
doi:10.1073/pnas.120163297 (2000).

105   Odds, F. C., Brown, A. J. & Gow, N. A. Candida albicans genome sequence: a platform
for genomics in the absence of genetics. *Genome Biol* **5**, 230, doi:10.1186/gb-2004-5-7-
230 (2004).

106   Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene
expression variation inferred from GWAS summary statistics. *Nat Commun* **9**, 1825,
doi:10.1038/s41467-018-03621-1 (2018).

107   Battle, A., Brown, C. D., Engelhardt, B. E. & Montgomery, S. B. Genetic effects on gene
expression across human tissues. *Nature* **550**, 204-213, doi:10.1038/nature24277
(2017).

AUTHOR CONTRIBUTIONS

A.T.H. and E.R.G. conceived and designed the study. A.T.H., D.Z., R.L.S., L.B., S.J.S., D.C.K.,
and E.R.G. contributed new methodologies. A.T.H., D.Z., R.L.S., L.B., L.W., S.S.Z., S.J.S.,
D.C.K., and E.R.G acquired, processed, and analyzed data. A.T.H. and E.R.G. drafted the
manuscript. All authors critically revised the manuscript for important intellectual content.

ACKNOWLEDGEMENTS

A.T.H. is supported by the National Institutes of Health (F30HL143826) and Vanderbilt
University Medical Scientist Training Program (T32GM007347). E.R.G. is supported by the
National Human Genome Research Institute of the National Institutes of Health under Award
Numbers R35HG010718 and R01HG011138. E.R.G. and S.S.Z. are funded by the National
Heart, Lung, & Blood Institute of the National Institutes of Health under Award Number
R01HL133559. The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health. E.R.G. has also significantly
benefitted from a Fellowship at Clare Hall, University of Cambridge (UK) and is grateful to the
President and Fellows of the college for a stimulating intellectual home. Genomic data are also
supported by individual investigator-led projects including U01-HG004798, R01-NS032830,
RC2-GM092618, P50-GM115305, U01-HG006378, U19-HL065962, and R01-HD074711.
Additional funding sources for BioVU are listed at https://victr.vanderbilt.edu/pub/biovu/. L.B. is
supported by R01-LM010685. S.J.S. is supported by an NIH Director's Pioneer and
Transformative Awards DP1-HD086071 and R01-AI145057. D.C.K. is supported by R01-
AI118903, R21-AI144586, and R21-AI146520. D.C.K. and L.W. are supported by R21-AI133305.

COMPETING INTERESTS

FIGURE LEGENDS

Figure 1. Overview of ID atlas resource. List of ID traits tested with corresponding Phecode (phewascatalog.org) in parentheses.

Figure 2. Genome-wide association study (GWAS) of ID traits. (A) Threshold for inclusion of
SNP associations was set at 1.0×10^{-4}. Genome-wide significance for an ID trait was set at the
conventional GWAS threshold $p = 5.0 \times 10^{-8}$, as indicated by the horizontal dotted line. The
subset of 13 ID traits (among the full set tested) with variants that meet the traditional genome-
wide significance threshold are included. The top variant association for each of the 13 traits is
labeled. The most significant variant association is with bacterial pneumonia ($p < 1.0 \times 10^{-30}$). (B)
LocusZoom plot at the sentinel variant, rs17139584, associated with bacterial pneumonia.
Several variants in low LD ($r^2 < 0.20$) with the sentinel variant, including variants in the cystic
fibrosis gene *CFTR* and in the *MET* gene >650 Kb upstream, are genome-wide significant for
bacterial pneumonia. The sentinel variant remains statistically significant ($p = 0.007$) after
adjusting for a diagnosis of cystic fibrosis.
1007

1009

Figure 3. Transcriptome-wide association studies (TWAS) of 35 ID traits reveal novel ID-associated genes. The genetic component of gene expression for autosomal genes was individually tested for association with each of 35 ID traits (see Methods). (A) Experiment-wide or ID-specific significant genes are displayed on the ideogram using their chromosomal locations and color-coded using the associated ID traits. Most associations represent unique genes within the implicated loci, suggesting the genes are not tagging another causal gene. A locus on chromosome 9, by contrast, shows multiple associations with the same ID trait, which may indicate correlation of the expression traits with a single causal gene in the locus. Circle: European ancestry cohort. Diamond: African American ancestry. (B) Manhattan plot shows the PrediXcan associations with sepsis (Phecode 994; number of cases 2,921; number of controls 22,874). Dashed line represents $p < 5 \times 10^{-5}$. The gene *IKZF5* was significant ($p = 8.16 \times 10^{-7}$, adjusted $p < 0.05$) after Bonferroni correction for the number of genes tested. (C) Q-Q plot of FinnGen replication p-values for genes associated with intestinal infection ($p < 0.05$) in BioVU (red) compared to the remaining set of genes (black). The ID-associated genes tended to be more significant in the independent dataset than the remaining genes, as evidenced by the leftward shift in the Q-Q plot. (D) Q-Q plot of UK Biobank replication p-values for influenza in lung tissue demonstrating significant deviation from null expectation. The horizontal line corresponds to the Bonferroni threshold (adjusted $p < 0.05$). (E) Q-Q plot of the full set of FinnGen p-values from the association of gene expression in cerebellum with meningitis (blue) vs. the subset of FinnGen (replication) p-values for the top BioVU meningitis gene-level associations in cerebellum (red). The meningitis associated genes in BioVU dramatically improve signal-to-noise ratio, as shown by the leftward shift in the Q-Q plot. The horizontal line corresponds to the Bonferroni threshold (adjusted $p < 0.05$) based on the number of top BioVU genes tested.

Figure 4. Enriched pathways across multiple ID traits and pathogen evolutionary strategies to
promote infection. (A) Gene set enrichment analysis of ID associated genes having also
nominal associations with additional ID traits. All gene sets satisfied false discovery rate < 0.05
for pathway enrichment and included known biological processes (e.g. protein complex
formation, cytoskeletal protein binding, cell death, actin motility, etc.) relevant to the biology of
infection. (B) Highly conserved motif "TCCCRNNRTGC", within 4 kb of the transcription start
site (TSS) of ID-associated genes, is enriched among the multi-ID associated genes and does
not match any known transcription factor binding site. Genes with this motif near the TSS
include *AKIRIN2*, *CDK5*, *RAD50*, *PTCD3*, and *CERS3*. This suggests a strategy that the
pathogens may broadly exploit to hijack the host transcriptional machinery. (C) CDK5 is an
example of a multi-ID associated gene, significantly associated with Gram-positive septicemia
and nominally associated with other IDs, including herpes simplex virus. CDK5 is activated by
its regulatory subunit p35/p25. The CDK5-p25 complex regulates inflammation (whose large-
scale disruption is characteristic of septicemia) and induces cytoskeletal disruption in neurons
(where the herpes virus promotes lifelong latent infection). Structure of the CDK5-p25 complex
(PDB: 1H4L, [44]) is shown here. The A and B chains are required for cytoskeletal protein binding
(CDK5), whereas the D and E chains (p25) are involved in actin regulation and kinase function,
all functions implicated in our pathway analysis. (D) Multi-ID associated genes identified by our
study have also been observed in host-pathogen protein complexes (by coimmunoprecipitation,
affinity chromatography, and two-hybrid approaches, among others) for the specific pathogens
responsible for the ID traits. Interactions of pathogen proteins with CDK5 are shown here.
M2_134A1 (UniProt: PO6821) is the matrix protein 2 component of the proton-selective ion
channel required for influenza A viral genome release during cellular entry and is targeted by
the anti-viral drug amantadine[48]. VE7_HPV16 (UniProt: PO3129) is a component of human
papillomavirus (HPV) required for cellular transformation and trans-activation through
disassembly of E2F1 transcription factor from RB1 leading to impaired production of type I
interferons[49-51]. VE7_HPV31 (UnitProt: P17387) engages histone deacetylases 1 and 2 to
promote HPV31 genome maintenance[52]. VCYCL_HHV8P (UniProt: Q77Q36) is a cyclin
homolog within the human herpesvirus 8 genome that has been shown to control cell cycle
through CDK6 and induce apoptosis through Bcl2[53-55]. F5HC81_HHV8 (UniProt: F5HC81) is not
well-characterized, but predicted to act as a viral cyclin homolog. This suggests a second
strategy that the pathogens exploit, i.e., alteration of the host proteome, to promote infection.

1069
1070

Figure 5. Pathogen genus identification from gut microbiome and clinical blood cultures linked
to whole-genome information reveals insights into host colonization and infection. (A) Bacterial
and fungal pathogens identified from blood (n = 7,699 positive cultures across 94 genera) from
2,417 individuals. (B) Area under the receiver operating characteristic curve (AUC) showing that
the clinical trait *Staphylococcus* infection (Phecode = 041.1) performs well in classifying
Staphylococcus aureus infection based on blood culture data from (A), with AUC of 0.938 with
standard error of 0.008. The first PC in the European ancestry samples and a model with age,
sex, and the first 5 PCs, both with substantially lower performance (AUC of 0.514 and 0.568,
respectively), are also shown. (C) Q-Q plot of top SNPs (p < 0.0001) associated with
Desulfovibrionaceae colonization in the human gut microbiome showing the p-value distribution
from the association with intestinal infection (Phecode 008) in BioVU. Note the enrichment as
shown by the leftward shift relative to the diagonal line, with several genes satisfying the
FDR<0.05 (red line) threshold.
1084

Figure 6. Phenome-scale scan of 70 ID-associated genes across 197 cardiovascular,
hematologic, neurologic, and respiratory phenotypes (cases > 200) in BioVU
(phewascatalog.org) identifies genes association with both disease risk and corresponding
known complications of the infection. (A) Each dot represents the association of an ID-
associated gene with one of the 197 (hematologic, respiratory, cardiovascular, and neurologic)
phenotypes. Horizontal red line indicates threshold for statistical significance correcting for
number of phenotypes and ID-associated genes tested. We identify four gene-phenotype pairs
reaching experiment-wide significance (adjusted $p < 0.05$): 1) *WFDC12*, our most significant (p
$= 4.23\times10^{-6}$) association with meningitis, is also associated with cerebral edema and
compression of brain ($p = 1.35\times10^{-6}$), a feared clinical complication of meningitis[62]; 2) *TM7SF3*,
the most significant gene with Gram-negative sepsis ($p = 1.37\times10^{-6}$), is also associated with
acidosis ($p = 1.95\times10^{-6}$), a known metabolic derangement associated with severe sepsis[63]; 3)
TXLNB, the most significant gene associated with viral warts and human papillomavirus
infection ($p = 4.35\times10^{-6}$), is also associated with abnormal involuntary movements, $p = 1.39\times10^{-6}$;
and 4) *RAD18*, the most significant gene associated with Streptococcus infection ($p = 2.01\times10^{-6}$),
is also associated with anemia in neoplastic disease ($p = 3.10\times10^{-6}$). (B) Mendelian
randomization framework. P-value threshold used to define an instrumental variable was set at
$p < 1.0\times10^{-5}$ and variants in linkage equilibrium ($r^2 = 0.01$) were used. (C) Mendelian
Randomization provides strong support for causal exposure-outcome relationships for 1)
meningitis and compression of brain (left, median-weighted estimator $p = 2.7\times10^{-3}$); and 2)
gram-negative septicemia and acidosis (right, median-weighted estimator $p = 2.0\times10^{-7}$). Grey
lines indicate 95% confidence interval.

Figure 7. TWAS of 79 pathogen-exposure induced cellular traits improves identification of
pathogen-induced cellular mechanisms. (A) Genes reaching significance in Hi-HOST after
correction for the total number of genes and cellular phenotypes tested. (B) Integration of EHR
data into Hi-HOST facilitates replication of gene-level associations with a clinical ID trait. Genes
nominally associated (p < 0.05) with Gram-positive septicemia (Phecode 038.2) in BioVU show
significant enrichment for *Staphylococcus* toxin exposure, a Hi-HOST phenotype. The Q-Q plot
shows the distribution of TWAS p-values in the Hi-HOST data for the top genes in the BioVU
data. False discovery rate (FDR) thresholds at 0.25 (blue), 0.10 (green), and 0.05 (red) are
shown. (C) Integration of EHR data into Hi-HOST also improves the signal-to-noise ratio in Hi-
HOST. For example, the top 300 genes nominally associated with *Staphylococcus* infection
(Phecode 041.1) in BioVU (p < 0.016, red) depart from null expectation for their TWAS
associations with *Staphylococcus* toxin exposure in Hi-HOST compared to the full set of genes
(black).
1125
1126

1128
1129

Table 1. Significant trait-specific gene-level associations with individual infectious disease phenotypes (for which number of cases > 100). Experiment-wide significant findings (adjusted p < 0.05) are noted in **bold**.

1133

Gene	Phecode	Phenotype	Cases	Controls	Ancestry	Odds ratio	P valu
IKZF5	994	Sepsis	2,921	22,874	European	0.91	8.16x1
AKIRIN2	112	Candidiasis	2,284	21,426	European	0.91	2.83x1
PSMG1	041.1	*Staphylococcus* infection	2,180	19,844	European	0.90	3.13x1
AGTR1	079	Viral infection	1,811	20,904	European	1.12	1.49x1
SLC35F6	079	Viral infection	1,811	20,904	European	0.89	3.30x1
NDUFA4	**008**	**Intestinal infection**	**1,608**	**24,187**	**European**	**1.16**	**1.83x1**
C10orf120	**008**	**Intestinal infection**	**1,608**	**24,187**	**European**	**1.13**	**4.92x1**
RAD18	041.2	*Streptococcus* infection	1,262	19,844	European	1.16	2.01x1
MAPK8IP2	041.2	*Streptococcus* infection	1,262	19,844	European	1.14	3.81x1
AVIL	041.4	*Escherichia Coli*	1,231	19,844	European	1.16	1.58x1
STAP2	078	Viral warts and human papilloma virus	1,152	20,904	European	1.15	2.33x1
TXLNB	078	Viral warts and human papilloma virus	1,152	20,904	European	0.86	4.35x1
SLCO1A2	053	Herpes zoster	989	20,904	European	0.93	1.64x1
CLDN20	053	Herpes zoster	989	20,904	European	0.86	4.54x1
IGF2	041.9	Infection with drug-resistant organism	893	19,844	European	0.83	4.01x1
CERS3	041.9	Infection with drug-resistant organism	893	19,844	European	1.17	4.18x1
TOR4A	**480.1**	**Bacterial pneumonia**	**862**	**18,054**	**European**	**0.84**	**5.15x1**
FAM166A	480.1	Bacterial pneumonia	862	18,054	European	1.19	1.10x1
C9orf173	480.1	Bacterial pneumonia	862	18,054	European	1.18	4.48x1
PIP5K1A	480.1	Bacterial pneumonia	862	18,054	European	1.16	7.00x1
NELFB	480.1	Bacterial pneumonia	862	18,054	European	0.86	1.87x1
AVEN	480.1	Bacterial pneumonia	862	18,054	European	0.85	3.31x1
TM7SF3	038.1	Gram negative septicemia	820	19,844	European	1.17	1.37x1
RAD50	038.1	Gram negative septicemia	820	19,844	European	1.17	4.50x1
ZNF577	070.3	Viral hepatitis C	808	20,904	European	0.84	6.21x1
ZNF649	070.3	Viral hepatitis C	808	20,904	European	0.85	1.85x1
SETD9	**136**	**Other infectious and parasitic diseases**	**746**	**24,770**	**European**	**0.83**	**3.04x1**
AC022431.1	**136**	**Other infectious and parasitic diseases**	**746**	**24,770**	**European**	**1.20**	**7.92x1**
MYO1C	136	Other infectious and parasitic diseases	746	24,770	European	1.10	2.97x1
NUDT5	136	Other infectious and parasitic diseases	746	24,770	European	0.84	3.52x1
MAATS1	110	Dermatophytosis and dermatomycosis	654	3,330	African	0.80	4.82x1
PTPN4	**117**	**Mycoses**	**627**	**21,426**	**European**	**0.79**	**1.56x1**
WIPF1	117	Mycoses	627	21,426	European	1.20	2.72x1
ALX4	**038.2**	**Gram positive septicemia**	**613**	**19,844**	**European**	**1.25**	**4.21x1**
C22orf31	038.2	Gram positive septicemia	613	19,844	European	0.81	2.05x1
IL2RA	038.2	Gram positive septicemia	613	19,844	European	1.20	3.88x1
VWA5B1	008	Intestinal infection	368	4,060	African	1.30	3.85x1
ATP6V1C2	041.1	*Staphylococcus* infection	358	3,337	African	1.33	1.51x1
WDR66	481	Influenza	272	18,054	European	0.71	3.47x1
FAM20A	481	Influenza	272	18,054	European	077	1.51x1
HKDC1	481	Influenza	272	18,054	European	1.34	2.20x1
ASPSCR1	481	Influenza	272	18,054	European	1.35	2.76x1
FAM208A	041.4	*Escherichia Coli*	243	3,337	African	1.42	1.15x1
TBK1	041.2	*Streptococcus* infection	229	3,337	African	1.41	4.70x1
DNAJC5G	071	Human immunodeficiency virus	196	20,904	European	1.08	7.36x1
FABP4	070.2	Viral hepatitis B	166	20,904	European	0.70	4.39x1
ANK2	070.2	Viral hepatitis B	166	20,904	European	0.77	4.56x1
HIP1	041.9	Infection with drug-resistant organism	165	3,337	African	1.46	6.74x1
C11orf53	041.9	Infection with drug-resistant organism	165	3,337	African	0.72	4.98x1
EPCAM	**010**	**Tuberculosis**	**156**	**19,844**	**European**	**1.40**	**5.04x1**
AL589739.1	**010**	**Tuberculosis**	**156**	**19,844**	**European**	**1.55**	**9.46x1**
PROX2	010	Tuberculosis	156	19,844	European	1.40	9.70x1
USP44	010	Tuberculosis	156	19,844	European	1.44	1.07x1
GPRIN1	010	Tuberculosis	156	19,844	European	1.49	2.55x1
NSUN5	010	Tuberculosis	156	19,844	European	0.75	2.76x1
C19orf55/PROSER3	010	Tuberculosis	156	19,844	European	1.51	3.30x1
DNAJC17	054	Herpes simplex	154	3,241	African	0.65	2.75x1
CHMP5	054	Herpes simplex	154	3,241	African	1.36	2.22x1

Gene	Code	Description	Col4	Col5	Ancestry	Col7	Col8
GNRH1	054	Herpes simplex	154	3,241	African	1.47	4.64x1
TXNL1	152	Sexually transmitted infections excluding HIV and hepatitis	152	25,643	European	0.64	3.92x1
LTBP4	152	Sexually transmitted infections excluding HIV and hepatitis	152	25,643	European	0.70	2.13x1
CRYL1	152	Sexually transmitted infections excluding HIV and hepatitis	152	25,643	European	0.70	2.23x1
LIMK2	041.8	Helicobacter Pylori	150	19,844	European	0.71	2.88x1
WFDC12	320	Meningitis	144	25,170	European	1.16	4.23x1
TNNC2	071	Human immunodeficiency virus	139	3,241	African	1.44	2.49x1
PRELID2	071	Human immunodeficiency virus	139	3,241	African	1.47	2.68x1
PTCD3	**324**	**Other CNS infections and poliomyelitis**	**136**	**25,170**	**European**	**0.89**	**3.74x1**
ATG9A	324	Other CNS infections and poliomyelitis	136	25,170	European	0.76	2.46x1
EIF3M	078	Viral warts and human papilloma virus	136	3,241	African	1.48	3.22x1
CDK5	038.2	Gram positive septicemia	114	3,337	African	0.65	3.64x1

1134

1135

1136

1137

1138

1139

1140